Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
Analysis of Different Treatment Modalities and Clinical Outcomes in Advanced NSCLC Patients Progressing After First-Line Immune Checkpoint Inhibitor Therapy: An Observational Study Based on Real-World Data
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jianchun Duan, M.D.
- Phone Number: +8610-87788029
- Email: duanjianchun79@163.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100021
- Cancer Hospirtal, Chinese Academy of Medical Sciences
-
Contact:
- Jianchun Duan, M.D.
- Phone Number: +8610-87788029
- Email: duanjianchun79@163.com
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518116
- Cancer Hospirtal, Chinese Academy of Medical Sciences, Shenzhen
-
Contact:
- Jianchun Duan, M.D.
- Phone Number: +8613811259820
- Email: duanjianchun79@163.com
-
-
Shanxi
-
Taiyuan, Shanxi, China, 030013
- Shanxi Provincial Cancer Hospital
-
Contact:
- Jianchun Duan, M.D.
- Phone Number: +8613811259820
- Email: duanjianchun79@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Locally advanced or metastatic NSCLC that is not curable and confirmed by histological or cytological examination based on the 8th edition of AJCC staging.
- Previously received advanced first-line treatment based on immune checkpoint inhibitor drugs.
- Has a medical record of disease progression during the first-line treatment.
- Complete clinical and pathological data, such as age, gender, smoking history, primary tumor location, differentiation, metastatic site, and imaging and serological review as required.
Exclusion Criteria:
- First-line treatment with immune checkpoint inhibitor drugs was ≤ 2 cycles.
- Excluding patients with incomplete key baseline and treatment information.
- Have other potential factors that may affect the study results or result in the premature discontinuation, as determined by the investigator
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observation
Patients with advanced NSCLC who have received standard first-line immune checkpoint inhibitor therapy and have experienced disease progression.
Retrospective case screening and collection were conducted, and follow-up observations were carried out.
|
The patients' second-line treatment received and the follow-up observations were retrospectively collected.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months
|
The overall survival time of the patients enrolled.
|
Time from 2nd line treatment initiation to patient death from any cause, assessed up to 60 months
|
|
Progression Free Survival
Time Frame: Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months
|
The time of disease progression free survival.
|
Time from 2nd line treatment initiation to the first recorded progression event in the medical information system (radiographic report or physician assessment) or death from any cause, whichever occurs first, assessed up to 60 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate
Time Frame: From 2nd line treatment initiation, assessed up to 24 months
|
Overall response rate
|
From 2nd line treatment initiation, assessed up to 24 months
|
|
Disease control rate
Time Frame: From 2nd line treatment initiation, assessed up to 24 months
|
Disease control rate
|
From 2nd line treatment initiation, assessed up to 24 months
|
|
Immune-related adverse events
Time Frame: From 2nd line treatment initiation and before 3rd line treatment, assessed up to 24 months
|
Immune-related adverse events
|
From 2nd line treatment initiation and before 3rd line treatment, assessed up to 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jianchun Duan, M.D., Cancer Hospirtal Chinese Academy of Medical Sciences
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NCC-021875
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.